Deciphering Carbapenemase Gene Transmission in Carbapenem-Resistant Enterobacter cloacae

Study Background and Research Question

The global rise of carbapenem-resistant Enterobacteriaceae poses a significant threat to clinical medicine, particularly for severe infections where therapeutic options are limited. Among these, Enterobacter cloacae has become increasingly prevalent in healthcare settings, ranking third in detection rates behind Klebsiella pneumoniae and Escherichia coli in China. The COVID-19 pandemic, characterized by increased antibiotic usage and healthcare system disruptions, has further exacerbated the emergence and dissemination of multidrug-resistant organisms. However, detailed molecular epidemiological data on carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC), particularly regarding their chromosomal versus plasmid localization and transmission dynamics in clinical settings, have remained scarce. This study aimed to fill that gap, investigating the prevalence, genetic context, and transmissibility of CEGs in CREC isolates from eight tertiary hospitals in Guangdong Province during 2022–2024 (reference study).

Key Innovation from the Reference Study

A major advance of this study lies in its high-resolution mapping of CEG distribution and mobility within clinical CREC populations. By combining molecular typing, resistance profiling, and conjugation experiments, the authors provide a nuanced picture of how specific carbapenemase genes—most notably bla_NDM-1—are maintained and spread both vertically (within lineages) and horizontally (across strains) via mobile genetic elements during a period of heightened antimicrobial selection pressure. The work is especially timely, as it quantifies the extent to which plasmid-borne resistance determinants drive multidrug resistance in real-world hospital environments during the COVID-19 pandemic.

Methods and Experimental Design Insights

The study analyzed 54 non-duplicate CREC isolates from eight teaching hospitals, collected between December 2022 and June 2024. The authors utilized a multi-pronged approach:

• Plasmid Elimination and PCR: Variable temperature sodium dodecyl sulfate (SDS) plasmid curing was employed to distinguish between plasmid- and chromosomal-located CEGs. PCR screening targeted key resistance genes including bla_NDM-1, bla_IMP, and bla_KPC-2.
• Antibiotic Susceptibility Testing: The broth microdilution method quantified resistance profiles against a spectrum of antibiotics, including imipenem, cefepime, gentamicin, ciprofloxacin, levofloxacin, and combinations such as ceftazidime/avibactam.
• Conjugation Experiments: Plasmid transferability was tested via filter mating and subsequent PCR verification in recipient strains.
• Molecular Typing: ERIC-PCR and NTSYS cluster analysis delineated genotypic relationships among the isolates, elucidating potential transmission clusters.
• Mobile Genetic Element Analysis: Specific insertion sequences and transposons, such as ISEcp1, were surveyed to map resistance gene mobility.

This integrative approach enabled the researchers to dissect both the static and dynamic aspects of CEG distribution and transfer within and between hospital settings.

Core Findings and Why They Matter

The study's findings underscore the complexity and urgency of multidrug resistance in hospital-associated Gram-negative pathogens:

• High CEG Prevalence: 85.19% (46/54) of CREC isolates harbored carbapenemase-encoding genes, with bla_NDM-1 being predominant.
• Genetic Localization: 33.33% of isolates carried bla_NDM-1 on both chromosome and plasmid, while 46.30% had this gene only on plasmids. A minority carried bla_IMP or both bla_NDM-1 and bla_KPC-2 exclusively on plasmids.
• Resistance Phenotypes: CEG-positive isolates exhibited significantly higher resistance rates to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin, aligning with the growing challenge in the treatment of bacterial pneumonia and bronchitis caused by multidrug-resistant organisms.
• Plasmid Transferability: Conjugation experiments demonstrated a 95.65% success rate for CEG transfer, with nearly all bla_NDM-1 and all bla_IMP genes being mobilizable, highlighting the risk of horizontal gene dissemination in clinical environments.
• Mobile Elements: Six types of mobile genetic elements were detected, with ISEcp1 present in 87.04% of isolates; many strains harbored multiple element types, facilitating gene spread.
• Epidemiological Trends: The highest detection rates were in male patients, the elderly, respiratory medicine departments, and sputum samples, suggesting particular risk groups for surveillance and intervention.

Together, these findings from the reference study illuminate the mechanisms by which multidrug resistance can proliferate rapidly in hospital settings, especially under pandemic-driven antibiotic pressure, and underline the critical need for rigorous surveillance and molecular epidemiology in Gram-negative bacterial infection research.

Protocol Parameters

• Sample selection: Isolate CREC strains from diverse clinical departments and specimen types to capture full epidemiological spectrum.
• Plasmid curing: Apply variable temperature SDS treatment to discriminate between chromosomal and plasmid-localized resistance genes.
• PCR screening: Use primers for bla_NDM-1, bla_IMP, and bla_KPC-2 to characterize CEG content.
• Broth microdilution: Quantify minimum inhibitory concentrations for a panel of antibiotics, including third-generation cephalosporins and β-lactamase inhibitor combinations.
• Conjugation workflow: Perform filter mating assays with appropriate selection markers to assess gene transfer frequency.
• Genotyping: Employ ERIC-PCR and bioinformatic clustering to map transmission networks.

Comparison with Existing Internal Articles

The insights from this Guangdong-based epidemiological survey reinforce and extend findings presented in several recent methodological reviews. For example, "Ceftazidime in Gram-Negative Research: Protocols & Advantages" emphasizes the importance of robust antibiotic susceptibility workflows and troubleshooting multidrug resistance, aligning with the reference study’s demonstration of high resistance rates among CEG-positive CREC. Similarly, "Ceftazidime in Gram-Negative Infection Research: Protocols & Pitfalls" highlights ceftazidime’s pivotal role in dissecting resistance mechanisms in respiratory infection models—a relevant focus given the predominance of respiratory samples in the Guangdong cohort. These internal resources complement the reference study’s data by providing actionable laboratory protocols and practical guidance for researchers tackling Gram-negative resistance.

Limitations and Transferability

While this study offers valuable epidemiological and mechanistic insights, several limitations merit consideration. The sample size, though robust for a regional survey, may not capture all genetic diversity present in other geographic or healthcare settings. The focus on tertiary hospitals may also introduce bias, as community-acquired strains could display different resistance patterns. Further, the molecular analyses, while comprehensive, do not extend to whole-genome sequencing, which could provide additional resolution on horizontal gene transfer events. Despite these limitations, the workflow and findings are transferable to comparable hospital-based settings and can inform surveillance protocols and antibiotic stewardship strategies elsewhere.

Research Support Resources

To facilitate high-quality Gram-negative bacterial infection research—particularly for studies investigating multidrug resistance, transmission dynamics, and treatment efficacy—researchers can employ well-characterized reference antibiotics. Ceftazidime (SKU B3539), available from APExBIO, is a third-generation cephalosporin with established activity against Pseudomonas aeruginosa and other Gram-negative pathogens, and is notable for its β-lactamase resistance. Using validated compounds like ceftazidime can support reproducibility and comparability in multidrug resistance assays, as demonstrated in both the reference study and internal methodological articles. For specific workflow enhancements and troubleshooting in this research domain, further protocol recommendations are detailed in the cited internal resources above.